## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($1011.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 2)

**1. Indiana sues Eli Lilly alleging insulin price-fixing scheme**
- Source: WFYI | 20260105T200831 | Bearish | Relevance: 100%
- Indiana has filed a lawsuit against Indianapolis-based Eli Lilly and Company, accusing the pharmaceutical company of inflating insulin prices through a secret rebate scheme with pharmacy benefit managers. The state alleges Lilly conspired to artificially raise sticker prices for insulin, driving up costs for patients despite low manufacturing costs. Eli Lilly asserts it has taken industry-leading steps to lower insulin costs, including capping out-of-pocket expenses and cutting list prices.

**2. Indiana sues Eli Lilly over insulin prices**
- Source: WTHR | 20260105T110100 | Somewhat-Bearish | Relevance: 100%
- The state of Indiana is suing pharmaceutical giant Eli Lilly and Company, accusing it of colluding with other insulin makers to inflate insulin prices by over 1,000% in the last decade. Attorney General Todd Rokita is seeking market changes, damages, and penalties. Eli Lilly denies the allegations, stating it has made insulin more affordable and committed significant investment in the U.S.

**3. Lillyâ€™s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones**
- Source: BioSpace | 20260105T160930 | Bullish | Relevance: 100%
- Eli Lilly is projected to achieve $94.3 billion in annual revenue by 2027, with 2026 being a pivotal year driven by growth in the oral obesity drug market. Key milestones include the anticipated approval of Lilly's oral obesity drug orforglipron and the readout of crucial Phase III trials, as the company fiercely competes with Novo Nordisk. Analysts expect Lilly to maintain an edge in the oral obesity market due to its easier-to-manufacture small molecule drug candidates.

**4. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026**
- Source: Finviz | 20260105T135425 | Bullish | Relevance: 98%
- This article highlights five AI-powered medical stocks that are projected to build a strong portfolio in 2026. The medical sector has significantly adopted AI for diagnostics, drug synthesis, and operational efficiency, transforming some defensive low-beta stocks into high-growth providers. The featured companies are Eli Lilly and Co. (LLY), Medtronic plc (MDT), Intuitive Surgical Inc. (ISRG), Regeneron Pharmaceuticals Inc. (REGN), and Johnson & Johnson (JNJ), each leveraging AI to enhance their product offerings, operational efficiency, and market position.

**5. Indiana AG files state lawsuit against Eli Lilly over insulin prices**
- Source: Fox 59 | 20260105T140823 | Bearish | Relevance: 96%
- Indiana Attorney General Todd Rokita has filed a lawsuit against Eli Lilly and Company, alleging the drugmaker conspired to raise insulin prices. This lawsuit follows an earlier one against other manufacturers and pharmacy benefit managers, where Lilly was initially named as a co-conspirator but not a defendant. Rokita claims Lilly's pricing scheme caused insulin prices to rise over 1000% in the last decade, violating Indiana state acts.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($2.11M) |
| Sells | 24 ($205.93M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $206M sold (24 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.98 indicates undervaluation relative to growth. Forward P/E 32.6x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Insider selling cluster ($205.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $953.9B |
| Beta | 0.35 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.98 |
| Forward P/E | 32.6 |
| Current P/E | 45.0 |
| YoY Growth | 37.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.6% to -1.2% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-4.36), momentum weakening. RSI neutral at 56. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.16% (CS: 24) | Neutral |
| RSI_14 | 55.8 | Neutral |
| MACD Histogram | -4.36 | Bearish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.057x | Above |
| vs SMA200 | 1.282x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $1064.11
- **Stop Loss:** $1011.97 (4.9% risk)
- **Target:** $1116.25 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 25
- **Position Value:** $26,602.75
- **Portfolio %:** 26.60%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*